Abstract -The ubiquitin-proteasome proteolytic pathway has recently been reported to be of major importance in the breakdown of skeletal muscle proteins. The 
INTRODUCTION
Proteins in skeletal muscle, as in other mammalian tissues, undergo a continuous process of synthesis and degradation, which regulates the levels of specific proteins and the overall muscle protein mass [46] . For example, increased proteolysis contributes to the muscle wasting seen with fasting and several pathological conditions. In such states, enhanced protein breakdown in skeletal muscle, the major protein reservoir in the body, is a key metabolic adaptation providing the organism with free amino acids for energy production via increased gluconeogenesis and direct oxidation. In some instances, for example in sepsis, net mobilization of muscle protein also provides free amino acids for acute phase protein synthesis in the liver.
The lysosomal, Ca 2+ -activated and ubiquitin-proteasome-dependent pathways are the three major proteolytic processes widely believed to be responsible for the breakdown of proteins in skeletal muscle [1, 2] . In recent years, it has become apparent that both lysosomal and Ca 2+ -activated proteases (i.e. cathepsins and calpains, respectively) do not play a major role in this tissue: they contribute less than 15-20 % of total protein breakdown in muscles from control and cachectic animals, and are not responsible for the breakdown of myofibrillar proteins [15, 25, 41] . Furthermore, a systematic activation of either cathepsins or calpains has not been observed in several instances of muscle atrophy (see Attaix and Taillandier [1] for detailed information). By contrast, the activation of the ubiquitin-proteasome pathway is mainly responsible for the muscle wasting that prevails in various animal models of cachexia, as well as in some human diseases [1, 2, 29] . In this paper we critically review the evidence that this pathway is the major proteolytic process in skeletal muscle. We also discuss the impli- [9] and Baumeister et al. [7] for recent reviews). [5] and diabetes [34] , and seems to be specific to skeletal muscle. Increased ubiquitin mRNA levels were observed in both types I and II skeletal muscle fibers from starved rats, but not in liver, kidney and adipose tissue, which also undergo significant atrophy [28] . However, increased expression of ubiquitin was also reported in the heart [28] and intestines [37] of starved rats, and in skin from tumor-bearing animals [6] . It [10] . Although ubiquitin is a heat-shock protein, there was no coordinate increase in expression of other heatshock genes in the atrophying muscles from starved, denervated and cancer rats [6, 28] . The precise mechanisms which result in increased ubiquitin expression have not been elucidated. However, there is increased production of glucocorticoids in several catabolic states [35, 42, 47] , and glucocorticoid responsive elements have been detected in the promotors of the chicken and human polyubiquitin genes [4] . Ubiquitin expression is also regulated by insulin [22] , and presumably indirectly by several cytokines including tumor necrosis factor-a (TNF-a) [24] .
Ubiquitin-activating enzyme, El
The sequence of El is highly conserved in several species. The human gene possesses an alternative start codon, resulting in the expression of a 1058-residue nuclear form and a 1018-residue cytoplasmic form (see Haas and Siepmann [18] ). E l has low expression in skeletal muscle [19] . However, its mRNA level was regulated in biopsies from acidotic patients with renal failure [36] , and in atrophying muscles from hindlimb suspended rats (Taillandier and species. However, only the expression of the 14-kDa E2 was found to be regulated in muscle wasting [1] . The 14-kDa E2 has two transcripts (1.8 and 1.2 kb) arising from different polyadenylation sites [48] . The 1.8-kb transcript, which corresponds to the major mRNA species in rat muscle, is barely detectable in humans [26] and goats [22] [33] or acutely septic [45] rats, although in both conditions the activation of a ubiquitin-dependent proteolytic process was responsible for increased proteolysis. Furthermore, increased expression of the 14-kDa E2 also does not always correlate with enhanced protein breakdown [40] . The expression of the 14-kDa E2 is regulated by glucocorticoids in adult rats, but not in old animals [10] . In vitro, insulin and insulin-like growth factor I decrease the stability of the 14-kDa E2 mRNAs [49] . Such down-regulation, however, does not prevail in insulininfused animals [22] .
Ubiquitin-protein ligases, E3s
There are at least six distinct E3s in mammalian cells. These enzymes play a role in the selection of substrates targeted for degradation by the ubiquitin-proteasome system (see Haas and Siepmann [18] ). Unfortunately, very little is known about E3s in skeletal muscle, although thel4-kDa E2 is one of the major mammalian E2s that best supports E3-dependent conjugate formation and protein breakdown [20] . Gonen et al. [16] [40, 41] . In contrast, a decrease in ubiquitin-conjugates was observed during corticosterone treatment [4] . The reasons for such discrepancies are unclear, although it is conceivable that in some cases the changes in the levels of ubiquitin-conjugates may result from alteration in their rates of degradation. It has been observed that ubiquitylated proteins accumulate preferentially in the myofibrillar fraction [50] , although others report conflicting findings [41] . Therefore, the proteins that are preferentially ubiquitylated in skeletal muscle remain to be identified. It is noteworthy, however, that the levels of free ubiquitin in basal conditions are much higher than the dissociation constant for E1, the enzyme involved in the first step of ubiquitylation [17] reported to block the activation of the ubiquitin-proteasome pathway in acidosis [5] , diabetes [34] , denervation, sepsis, and following administration of thyroid hormones [39] . More [38] showed that the RC9 subunit enters active translation, when over-expressed in the atrophying muscles from unweighted rats. Finally, an increase in transcribed RC3 proteasome subunit mRNA is observed in acidosis [5] .
There seems to be a transcriptional programme that favours increased expression of all 20S proteasome subunits in muscle atrophy [29] . However, although upstream sequences of several 20S proteasomal genes have been described, potential regulatory elements have not yet been reported. Glucocorticoids [10, 33] and TNF-a [3] up-regulate mRNA levels for 20S proteasome subunits. By contrast, the expression of a and (3 subunits is not down-regulated by insulin [22] .
There is also growing evidence that changes in levels of subunit mRNAs of the 19S complex that binds to the 20S proteasome to form the 26S proteasome (figure 2) occur in various proteolytic conditions in skeletal muscle. However, the expression of ATPase and non-ATPase subunits of the 19S complex is regulated independently of the expression of 20S proteasome subunits, and clearly depends on a given catabolic state [3] . Furthermore, the mRNA levels and protein contents of the individual regulatory subunits are regulated independently, and do not always correlate with rates of protein breakdown [3] . These data are similar to the observations of Dawson et al. [11] [8] and Cushing's syndrome [35] [24] , and the administration of the glucocorticoid receptor antagonist RU 38486 in septic rats [42] blunted the increased ubiquitin expression in skeletal muscle. Unfortunately these compounds cannot be used easily in humans. Anti-TNF-a antibodies are prohibitively expensive, and clinical trials with RU 38486 (which was primarily used for its abortion-inducing properties) have been recently stopped. In order to circumvent such problems others have recently tried using pentoxifylline, a very low-cost drug that blocks TNF-a production and is well tolerated in humans even at high doses.
In these studies, treatment of Yoshida sarcoma-bearing rats with pentoxifylline or torbafylline (another xanthine derivative more potent than pentoxifylline) almost suppressed the cachexia, by inhibiting the activation of the ubiquitin-proteasome pathway [3] . Finally, the recent development of specific inhibitors of the proteasome and of ubiquitin conjugation [29] conceivably could lead to the design of future anti-cachectic therapies. However 
